The following hypersensitivity reactions have been reported: anaphylaxis, angioedema, pruritus, rash, serum sickness-like reaction, urticaria.
Hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia, and increased prothrombin time.
Hepatic impairment including hepatitis and cholestasis, jaundice.
Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
The following adverse events were thought by the investigators to be possibly, probably, or almost certainly related to Cefuroxime Axetil tablets in multiple-dose clinical trials: Diarrhea/loose stools, nausea/vomiting, transient elevation in AST, transient elevation in ALT, eosinophilia, transient elevation in LDH, abdominal pain, abdominal cramps, flatulence, indigestion, headache, vaginitis, vulvar itch, chills, rash, hives, itch, dysuria, chest pain.
Injection: Hypersensitivity reactions:
Including skin rashes (maculopapular and urticarial), interstitial nephritis, drug fever and, very rarely, anaphylaxis. As with any antibiotic, prolonged use may lead to overgrowth of non-susceptible organisms, eg, Candida.
As with other cephalosporins, there have been rare reports of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Including, very rarely, pseudomembranous colitis, nausea, vomiting, diarrhoea & cramps, which has been reported with most broad spectrum antibiotics.
A decrease in haemoglobin concentration, eosinophilia, leucopenia and neutropenia have been observed. Positive Coombs' tests have been reported. As with other cephalosporins, thrombocytopenia has been reported rarely.
Transient rises in liver enzymes or serum bilirubin have been observed, particularly in patients with pre-existing liver disease, but there is no evidence of hepatic involvement.
There may be some variation in the results of biochemical tests of renal function, but these results do not appear to be of clinical significance.
Transient pain may be experienced at the site of intramuscular injection. Occasionally thrombophlebitis may occur at the site of intravenous injection. A burning sensation may be observed after intravenous injection. Mild to moderate hearing loss has been reported in some children treated for meningitis. Dizziness and headache has been reported in patients receiving cefuroxime.